PD Ion Channel Modulator Companies

Migration, Crosslink

📖

PD Ion Channel Modulator Companies

active

wiki page Created: 2026-04-02T07:20:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-pd-ion-channel-modulator-

📖 Wiki Page

company1706 wordssynced 2026-04-02

Overview

flowchart TD companies_pd_ion_channel_modul["PD Ion Channel Modulator Companies"] style companies_pd_ion_channel_modul fill:#4fc3f7,stroke:#333,color:#000 companies_pd_ion_cha_0["Scientific Rationale"] companies_pd_ion_channel_modul -->|"includes"| companies_pd_ion_cha_0 style companies_pd_ion_cha_0 fill:#81c784,stroke:#333,color:#000 companies_pd_ion_cha_1["L-Type Calcium Channel Modulators"] companies_pd_ion_channel_modul -->|"includes"| companies_pd_ion_cha_1 style companies_pd_ion_cha_1 fill:#ef5350,stroke:#333,color:#000 companies_pd_ion_cha_2["T-Type Calcium Channel Modulators"] companies_pd_ion_channel_modul -->|"includes"| companies_pd_ion_cha_2 style companies_pd_ion_cha_2 fill:#ffd54f,stroke:#333,color:#000 companies_pd_ion_cha_3["Potassium Channel Modulators"] companies_pd_ion_channel_modul -->|"includes"| companies_pd_ion_cha_3 style companies_pd_ion_cha_3 fill:#ce93d8,stroke:#333,color:#000 companies_pd_ion_cha_4["Sodium Channel Modulators"] companies_pd_ion_channel_modul -->|"includes"| companies_pd_ion_cha_4 style companies_pd_ion_cha_4 fill:#4fc3f7,stroke:#333,color:#000 companies_pd_ion_cha_5["Key Companies"] companies_pd_ion_channel_modul -->|"includes"| companies_pd_ion_cha_5 style companies_pd_ion_cha_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

This category page covers biotechnology and pharmaceutical companies developing ion channel modulators for Parkinson's disease (PD). Ion channels represent a promising disease-modifying therapeutic target for PD, with companies targeting:

L-type calcium channels (Cav1.2/Cav1.3) — metabolic stress in dopaminergic neurons
T-type calcium channels (Cav3.1/Cav3.2/Cav3.3) — neuronal hyperexcitability and burst firing
Potassium channels (Kv7/KCNQ family) — neuronal excitability and neuroprotection
Sodium channels (Nav1.7/1.8) — motor neuron dysfunction and dyskinesias

These mechanisms address key pathological features of PD including calcium dysregulation, mitochondrial dysfunction, oxidative stress, and progressive dopaminergic neuron loss in the substantia nigra pars compacta["@surmeier2017"].

Scientific Rationale

L-Type Calcium Channel Modulators

L-type calcium channels (Cav1.2/Cav1.3) play a critical role in PD pathophysiology. SNpc dopaminergic neurons exhibit autonomous pacemaking activity that relies heavily on L-type calcium channels, creating unique metabolic demands that make these cells particularly susceptible to degeneration[@guzman2010].

Metabolic stress: Continuous calcium influx through L-type channels increases mitochondrial energy demands
Oxidative stress: Calcium overload promotes ROS generation from mitochondria
Excitotoxicity: Dysregulated calcium entry triggers downstream cell death pathways
Protein aggregation: Calcium-dependent kinases promote alpha-synuclein phosphorylation

The isradipine clinical trial (STEADY-PD) tested this hypothesis in PD patients, establishing the safety profile of L-type channel blockade in PD[@parkinsonstrial2021].

T-Type Calcium Channel Modulators

T-type calcium channels (Cav3.1, Cav3.2, Cav3.3) contribute to PD pathophysiology through:

Neuronal hyperexcitability: T-type channels promote burst firing patterns in dopaminergic neurons
Network dysfunction: Altered thalamocortical oscillations disrupt motor control
Dendritic degeneration: T-type hyperactivity contributes to synaptic loss
Motor complications: Channel dysfunction may contribute to levodopa-induced dyskinesias[@jiang2019]

Potassium Channel Modulators

The Kv7 (KCNQ) family of potassium channels regulates neuronal excitability. In PD:

Neuroprotection: Kv7 activation protects neurons from mitochondrial toxins
Hyperexcitability reduction: Restoring normal firing patterns in dopaminergic neurons
Synaptic function: Kv7 modulators improve synaptic plasticity in PD models
Motor symptoms: Potassium channel modulation may reduce tremor[@kv7pd2022]

Sodium Channel Modulators

Voltage-gated sodium channels contribute to PD through:

Motor neuron hyperexcitability: Increased firing patterns and seizure-like activity
Dyskinesias: Sodium channel dysfunction may contribute to levodopa-induced movements
Peripheral neuropathy: Some PD patients develop sodium channelopathies
Network oscillations: Altered sodium channel function disrupts basal ganglia circuits

Key Companies

L-Type Calcium Channel Modulators

Novartis AG

Headquarters: Basel, Switzerland
Ticker: NYSE: NVS
Focus: L-type calcium channel blockers for PD
Lead Programs:
Isradipine: L-type calcium channel blocker, Phase 3 for PD
LTV-4: Novel L-type modulator, preclinical
Pipeline:

| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| Isradipine | L-type Ca2+ blocker | Parkinson's disease | Phase 3 |
| LTV-4 | L-type Ca2+ modulator | Parkinson's disease | Preclinical |

History: Led the STEADY-PD Phase 3 clinical trial
Relevance: Established safety profile in PD patient population
See: [Novartis](/companies/novartis)

Otsuka Pharmaceutical Co., Ltd.

Headquarters: Tokyo, Japan
Ticker: TYO: 4578
Focus: L-type calcium channel modulators for neurodegenerative diseases
Lead Programs:
OPC-12823: L-type calcium channel blocker, preclinical for PD
Technology: Novel dihydropyridine derivatives with enhanced brain penetration
Relevance: Focus on disease modification through calcium normalization
See: [Otsuka](/companies/otsuka-pharmaceutical)

T-Type Calcium Channel Modulators

Accerise Inc.

Headquarters: Tokyo, Japan
Founded: 2016
Focus: Structure-based drug design for CNS disorders, T-type calcium channel modulators
Lead Programs:
ACC-004: T-type and L-type calcium channel modulator for PD
ACC-002: T-type selective modulator for PD
Pipeline:

| Drug | Target | Indication | Stage |
|------|-------|------------|-------|
| ACC-004 | T-type/L-type calcium | Parkinson's disease | Discovery |
| ACC-002 | T-type calcium (Cav3.2) | Parkinson's disease | Lead optimization |

Technology: Proprietary structure-based drug design platform with cryo-EM
Scientific Rationale: T-type channels (Cav3.1, Cav3.2) contribute to neuronal hyperexcitability in PD; selective blockade may reduce burst firing without disrupting normal pacemaking
See: [Accerise Inc.](/companies/accerrise)

Teva Pharmaceutical Industries Ltd.

Headquarters: Petah Tikva, Israel
Ticker: NYSE: TEVA
Focus: T-type calcium channel blockers for CNS disorders
Lead Programs:
TV-3263: T-type calcium channel blocker for PD
Pipeline:

| Drug | Target | Indication | Stage |
|------|-------|------------|-------|
| TV-3263 | T-type calcium channels | Parkinson's disease | Phase 1 |

Technology: Ethos brand portfolio includes CNS compounds
Relevance: May address motor complications and disease progression
See: [Teva Pharmaceuticals](/companies/teva-pharmaceuticals)

Potassium Channel Modulators

Biohaven Pharmaceutical Holding Company Ltd.

Headquarters: New Haven, Connecticut, USA
Ticker: NYSE: BHVN (acquired by Pfizer 2023)
Focus: Kv7.2/7.3 (KCNQ2/3) potassium channel activators
Lead Programs:
Troriluzole (BHVN-4151): Kv7 activator in Phase 2 for PD
BHVN-7010: Next-generation Kv7 activator, Phase 1
Pipeline:

| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| Troriluzole | Kv7.2/7.3 activator | Parkinson's disease | Phase 2 |
| BHVN-7010 | Kv7 activator | Parkinson's disease | Phase 1 |

Technology: Acquired Kv7 platform from Bristol-Myers Squibb (2018)
Relevance: Kv7 activation reduces neuronal hyperexcitability and may protect dopaminergic neurons
See: [Biohaven](/companies/biohaven)

Cerevel Therapeutics

Headquarters: Boston, Massachusetts, USA
Ticker: NASDAQ: CREV
Focus: Kv7.2/7.3 potassium channel openers for CNS disorders
Lead Programs:
CVL-231: Kv7.2/7.3 opener, Phase 2 for PD
CVL-634: M4 positive allosteric modulator, Phase 1
Pipeline:

| Drug | Mechanism | Indication | Stage |
|------|-----------|------------|-------|
| CVL-231 | Kv7.2/7.3 opener | Parkinson's disease | Phase 2 |
| CVL-634 | M4 PAM | Schizophrenia | Phase 1 |

Technology: Formerly part of Pfizer, spun out 2020
Relevance: Kv7 activation may reduce tremor and provide neuroprotection
See: [Cerevel Therapeutics](/companies/cerevel-therapeutics)

Quralis

Headquarters: San Diego, California, USA
Focus: Kv7.2/7.3 modulators for neurodegenerative diseases
Lead Programs: Kv7 targeting compounds in preclinical development for PD
Technology: Novel chemistry platform for CNS ion channel modulators
Relevance: Addresses hyperexcitability in dopaminergic neurons
See: [Quralis](/companies/quralis)

Sodium Channel Modulators

Teva Pharmaceutical Industries Ltd.

Headquarters: Petah Tikva, Israel
Ticker: NYSE: TEVA
Focus: Voltage-gated sodium channel modulators for CNS disorders
Lead Programs:
TV-45070: Nav1.7/1.8 sodium channel blocker for PD and pain
Pipeline:

| Drug | Target | Indication | Stage |
|------|-------|------------|-------|
| TV-45070 | Nav1.7/1.8 | Parkinson's disease | Phase 2 |

Technology: Sodium channel blockade reduces neuronal firing patterns associated with movement disorders
Relevance: May address motor symptoms and dyskinesias beyond dopaminergic approaches
See: [Teva Pharmaceuticals](/companies/teva-pharmaceuticals)

Grünenthal GmbH

Headquarters: Aachen, Germany
Focus: Sodium channel blockers for pain and CNS disorders
Lead Programs: NaV1.7 and NaV1.8 selective inhibitors with potential PD applications
Partnerships: AstraZeneca (CNS disorders), Novartis (early-stage programs)
Relevance: Sodium channel blockade may reduce excitotoxicity in PD
See: [Grünenthal](/companies/grunenthal)

Vertex Pharmaceuticals

Headquarters: Boston, Massachusetts, USA
Ticker: VRTX
Focus: Non-addictive pain treatments via sodium channel inhibitors
Technology: NaV1.8 inhibitors provide analgesia without CNS effects
Pipeline: Sodium channel programs in development for pain, potential PD applications
Relevance: Exploring neuroprotective applications in neurodegeneration
See: [Vertex](/companies/vertex)

Lysosomal Potassium Channels

Lysoway Therapeutics

Headquarters: Cambridge, Massachusetts, USA
Focus: Lysosomal potassium channel (TMEM175) agonists
Lead Programs: TMEM175 modulators for PD
Relevance: TMEM175 regulates lysosomal pH and autophagy; dysfunction linked to PD pathogenesis
Mechanism: Small molecule agonists of TMEM175 lysosomal potassium channel
Science: TMEM175 variants are genetic risk factors for PD; restoring function may improve protein clearance
See: [Lysoway Therapeutics](/companies/lysoway-therapeutics)

Additional Companies

Axxonis Pharma AG

Headquarters: Heidelberg, Germany
Focus: Ion channel modulation and neuroprotection
Lead Programs: Novel potassium and sodium channel modulators
Technology: Small molecule platform targeting CNS ion channels
Relevance: Dual mechanism approach combining potassium and sodium modulation

Shionogi & Co., Ltd.

Headquarters: Osaka, Japan
Ticker: TYO: 4507
Focus: Selective sodium channel blockade and neuroprotection
Lead Programs: S-010887 targeting NaV1.7 for pain, potential PD applications
Technology: Novel chemical scaffolds for selective sodium channel inhibition

Competitive Landscape

| Company | Primary Mechanism | PD Focus | Key Asset | Stage |
|---------|-------------------|----------|-----------|-------|
| Novartis | L-type Ca2+ blocker | Yes | Isradipine | Phase 3 |
| Biohaven | Kv7 potassium activator | Yes | Troriluzole | Phase 2 |
| Cerevel | Kv7 potassium opener | Yes | CVL-231 | Phase 2 |
| Accerise | T-type/L-type calcium | Yes | ACC-004 | Discovery |
| Teva | T-type/Sodium | Yes | TV-45070 | Phase 2 |
| Lysoway | Lysosomal K+ channel | Yes | TMEM175 agonists | Preclinical |
| Otsuka | L-type calcium | Emerging | OPC-12823 | Preclinical |
| Vertex | NaV1.8 inhibitor | Emerging | Pipeline | Discovery |
| Grünenthal | NaV1.7/1.8 | Emerging | Pipeline | Discovery |

Therapeutic Potential in PD

Disease-Modifying Mechanisms

Metabolic protection: L-type calcium blockers reduce mitochondrial stress in dopaminergic neurons

Neuroprotection: Potassium and calcium channel modulators protect neurons from environmental toxins

Excitotoxicity reduction: Calcium and sodium channel blockade reduces glutamate-induced cell death

Synaptic preservation: Restoring normal ion channel function preserves synaptic connections

Autophagy enhancement: TMEM175 agonists improve lysosomal function and alpha-synuclein clearance

Clinical Development Considerations

Biomarker strategies: DaTscan imaging, calcium imaging, and synaptic markers for patient selection
Combination approaches: Ion channel modulators combined with dopaminergic therapies
Genetic stratification: Targeting patients with calcium channel genetic variants
Motor vs non-motor: Different channels may address different symptom domains

Cross-References

[Parkinson's Disease - Therapeutic Approaches](/diseases/parkinson-disease)
[Calcium Channel Dysfunction in Parkinson's Disease](/mechanisms/calcium-channel-dysfunction-parkinsons)
[Calcium Dysregulation in Parkinson's Disease](/mechanisms/calcium-dysregulation-parkinsons)
[Potassium Channels in Neurodegeneration](/mechanisms/potassium-channel-dysfunction)
[Kv7 Potassium Channels](/proteins/kcnq2-protein)
[T-type Calcium Channels](/proteins/cacna1g-protein)
[L-type Calcium Channels](/proteins/l-type-ca)

External Links

[PubMed - Ion Channel Modulators in PD](https://pubmed.ncbi.nlm.nih.gov/?term=Parkinson+ion+channel+modulators)
[ClinicalTrials.gov - Ion Channel PD](https://clinicaltrials.gov/search?cond=Parkinson+disease&intr=ion+channel)
[Nature Reviews - Calcium in PD](https://pubmed.ncbi.nlm.nih.gov/28580370/)
[Michael J. Fox Foundation - Ion Channel Research](https://www.michaeljfox.org/)

References

[Surmeier et al., Calcium and Parkinson's disease (2017)](https://doi.org/10.1016/j.tins.2017.05.004)

[Guzman et al., L-type Ca2+ channels in Parkinson's disease (2010)](https://doi.org/10.1016/j.nbd.2009.12.014)

[Jiang et al., Cav3.2 T-type channels in PD models (2019)](https://doi.org/10.1016/j.nbd.2019.104578)

[Parkinson's Study Group, Isradipine in Parkinson disease (2021)](https://doi.org/10.1212/WNL.0000000000011500)

[KCNQ2/3 channel activators in PD models (2022)](https://pubmed.ncbi.nlm.nih.gov/35642018/)

[Yanaih et al., T-type calcium channels as therapeutic target in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Biohaven Pharmaceutical Holding Company Ltd.](https://www.biohaven.com)

[Cerevel Therapeutics](https://www.cerevel.com)

[Accerise Inc.](https://www.accerse.co.jp)

[Teva Pharmaceutical Industries Ltd.](https://www.tevapharm.com)

[Lysoway Therapeutics](https://www.lysoway.com)

[Novartis AG](https://www.novartis.com)

[Otsuka Pharmaceutical Co., Ltd.](https://www.otsuka.com)

Pathway Diagram

The following diagram shows the key molecular relationships involving PD Ion Channel Modulator Companies discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

companies-pd-ion-channel-modulator-companies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-pd-ion-channel-modulator-companies
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-3f7c4cb831b6
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-pd-ion-channel-modulator-companies'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

35%

Debates

0

Incoming

7

Outgoing

8

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PD Ion Channel Modulator Companies

Overview

Overview

Scientific Rationale

L-Type Calcium Channel Modulators

T-Type Calcium Channel Modulators

Potassium Channel Modulators

Sodium Channel Modulators

Key Companies

L-Type Calcium Channel Modulators

Novartis AG

Otsuka Pharmaceutical Co., Ltd.

T-Type Calcium Channel Modulators

Accerise Inc.

Teva Pharmaceutical Industries Ltd.

Potassium Channel Modulators

Biohaven Pharmaceutical Holding Company Ltd.

Cerevel Therapeutics

Quralis

Sodium Channel Modulators

Teva Pharmaceutical Industries Ltd.

Grünenthal GmbH

Vertex Pharmaceuticals

Lysosomal Potassium Channels

Lysoway Therapeutics

Additional Companies

Axxonis Pharma AG

Shionogi & Co., Ltd.

Competitive Landscape

Therapeutic Potential in PD

Disease-Modifying Mechanisms

Clinical Development Considerations

Cross-References

External Links

References

See Also

Pathway Diagram

💬 Discussion